Addo Frank Bedu - Feb 28, 2024 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

Role
President/CEO, Director
Signature
/s/ Spencer Brown, Attorney-in-Fact
Stock symbol
PDSB
Transactions as of
Feb 28, 2024
Transactions value $
$0
Form type
4
Date filed
7/25/2025, 06:12 PM
Previous filing
Jan 6, 2023
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BEDU-ADDO FRANK President/CEO, Director C/O PDS BIOTECHNOLOGY CORPORATION, 303A COLLEGE ROAD EAST, PRINCETON /s/ Spencer Brown, Attorney-in-Fact 2025-07-25 0001770756

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PDSB Employee Stock Option (Right to Buy) Award $0 +300K $0.00 300K Feb 28, 2024 Common Stock 300K $5.87 Direct F1
transaction PDSB Employee Stock Option (Right to Buy) Award $0 +150K $0.00 150K Jun 12, 2025 Common Stock 150K $1.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on February 28,2025, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
F2 The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on June 12, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.